Cencora reports Q3 sales of $80.66 billion and EPS of $4.00, both above estimates, driven by GLP-1 and specialty drug demand in U.S. markets.
Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook
Where Today's News Shapes Tomorrow
